Pfizer Stock Price, News & Analysis

Pfizer has announced a €90.5 million ($95 million) investment in Valneva, acquiring an 8.1% stake in the company. This investment is aimed at supporting the development of VLA15, a Lyme disease vaccine candidate, with the Phase 3 study set to begin in Q3 2022. Pfizer will also update the collaboration agreement with Valneva, increasing Valneva's contribution to 40% of shared development costs. The total potential milestone payments to Valneva remain at $168 million, with royalties adjusted to a tiered range of 14% to 22%.

Pfizer Inc. and BioNTech SE have received FDA emergency use authorization for their COVID-19 vaccine, now available for children aged 6 months to 4 years. The 3-µg dose showed a strong immune response and a favorable safety profile similar to the placebo in a Phase 2/3 clinical trial involving 4,526 children. The trial demonstrated immunogenicity comparable to older age groups, meeting regulatory non-inferiority criteria. The vaccine rollout is anticipated to begin following CDC recommendations, ensuring free access for U.S. residents.

Pfizer's EPIC-SR study of PAXLOVID, targeting standard-risk COVID-19 patients, did not achieve its primary endpoint of sustained symptom relief. However, secondary analyses indicated a nominally significant 62% reduction in COVID-related medical visits. The company will halt enrollment in the EPIC-SR trial, focusing instead on high-risk populations due to low hospitalization rates. Data from this study will be included in the upcoming NDA submission to the FDA. Despite these challenges, Pfizer maintains that PAXLOVID's efficacy and safety profile is supported by data across multiple studies.

Pfizer, MorphoSys, and Incyte announced a clinical trial collaboration to explore the immunotherapeutic combination of Pfizer's TTI-622 with MorphoSys's Monjuvi and lenalidomide for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not eligible for autologous stem cell transplantation. Pfizer will lead a multicenter Phase 1b/2 study, which is set to take place in North America, Europe, and Asia-Pacific. The initiative addresses significant unmet medical needs in DLBCL treatment and follows promising preclinical data regarding TTI-622's potential efficacy.

Pfizer (NYSE: PFE) has successfully acquired ReViral, a clinical-stage biopharmaceutical company specializing in antiviral therapeutics for respiratory syncytial virus (RSV), for up to $525 million. This acquisition enhances Pfizer's anti-infective pipeline with promising candidates like sisunatovir, which has shown significant efficacy in clinical studies. The potential annual revenue for these programs could exceed $1.5 billion. This strategic move underscores Pfizer's commitment to advancing innovative therapies for serious infectious diseases.

Pfizer Inc. (NYSE: PFE) will host a webcast on June 16, 2022, featuring Mikael Dolsten, Chief Scientific Officer, at the Storebrand Conference: Invest in the Future. The event starts at 11:40 a.m. CEST (5:40 a.m. EDT). Investors can access the live presentation and register through www.pfizer.com/investors. A transcript and replay will be available within 24 hours post-event for 90 days. Pfizer emphasizes its commitment to health advancements and innovation, impacting global healthcare.

Pfizer Inc. (NYSE: PFE) is hosting a webcast discussion with Chief Scientific Officer Mikael Dolsten and Chief Development Officer William Pao at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15, 2022, at 8:40 a.m. PDT. Interested parties can access the webcast at www.pfizer.com/investors. The transcript will be available within 24 hours and accessible for at least 90 days. Pfizer focuses on innovative therapies and vaccines to enhance patient lives and actively engages in global health initiatives.

Pfizer Inc. (NYSE: PFE) announced a $120 million investment to expand its manufacturing capabilities at the Kalamazoo, Michigan facility, creating over 250 high-skilled jobs. This initiative aims to enhance production of active pharmaceutical ingredients (APIs) for PAXLOVID, its COVID-19 oral treatment. Since 2017, Pfizer has invested $5 billion in U.S. manufacturing. The Kalamazoo site will become one of the world’s largest API producers, boosting the supply capacity of PAXLOVID to meet growing global demand.

Pfizer Inc. (NYSE:PFE) announced overall survival results from the Phase 3 PALOMA-2 trial evaluating IBRANCE® (palbociclib) with letrozole in first-line treatment for postmenopausal women with HR+, HER2- metastatic breast cancer. With a median follow-up of 90 months, the study showed a median overall survival of 53.9 months for the treatment group versus 51.2 months for the control, though the results were not statistically significant (HR=0.956). The trial's primary endpoint was progression-free survival, previously met in 2016.